Insights into the Molecular Mechanisms Behind Intralesional Immunotherapies for Advanced Melanoma
Published 2020 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Insights into the Molecular Mechanisms Behind Intralesional Immunotherapies for Advanced Melanoma
Authors
Keywords
-
Journal
Cancers
Volume 12, Issue 5, Pages 1321
Publisher
MDPI AG
Online
2020-05-22
DOI
10.3390/cancers12051321
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Talimogene laherparepvec (T‐ VEC ) in advanced melanoma: complete response in a heart and kidney transplant patient. A case report
- (2019) J. Ressler et al. BRITISH JOURNAL OF DERMATOLOGY
- Recent insights on the role and regulation of retinoic acid signaling during epicardial development
- (2019) Suya Wang et al. GENESIS
- Real-World Outcomes of Talimogene Laherparepvec Therapy: A Multi-Institutional Experience
- (2019) Raphael J. Louie et al. JOURNAL OF THE AMERICAN COLLEGE OF SURGEONS
- ALDH1A3-regulated long non-coding RNA NRAD1 is a potential novel target for triple-negative breast tumors and cancer stem cells
- (2019) Dejan Vidovic et al. CELL DEATH AND DIFFERENTIATION
- Intralesional interleukin‐2: A novel option to maximize response to systemic immune checkpoint therapy in loco‐regional metastatic melanoma
- (2019) Ewan A. Langan et al. Dermatologic Therapy
- Correlates of response and outcomes with talimogene laherperpvec
- (2019) Alice Y. Zhou et al. JOURNAL OF SURGICAL ONCOLOGY
- Autoimmunity, checkpoint inhibitor therapy and immune-related adverse events: A review
- (2019) Shaheen Khan et al. SEMINARS IN CANCER BIOLOGY
- Retinoic acid and arsenic trioxide induce lasting differentiation and demethylation of target genes in APL cells
- (2019) Thomas T. Huynh et al. Scientific Reports
- Successful combination therapy of systemic checkpoint inhibitors and intralesional interleukin-2 in patients with metastatic melanoma with primary therapeutic resistance to checkpoint inhibitors alone
- (2019) David Rafei-Shamsabadi et al. CANCER IMMUNOLOGY IMMUNOTHERAPY
- Antigen presentation and tumor immunogenicity in cancer immunotherapy response prediction
- (2019) Shixiang Wang et al. eLife
- Successful treatment of cutaneous metastatic melanoma with high-dose intralesional interleukin-2 treatment combined with cryosurgery
- (2018) Antonio Martinez-Lopez et al. Dermatologic Therapy
- T Cells Dominate the Local Immune Response Induced by Intralesional IL-2 in Combination with Imiquimod and Retinoid for In-Transit Metastatic Melanoma
- (2018) Hiromi Ogawa et al. JOURNAL OF INVESTIGATIVE DERMATOLOGY
- Intralesional PV-10 for the treatment of in-transit melanoma metastases-Results of a prospective, non-randomized, single center study
- (2018) Tavis A. Read et al. JOURNAL OF SURGICAL ONCOLOGY
- Potential clinical and immunotherapeutic utility of talimogene laherparepvec for patients with melanoma after disease progression on immune checkpoint inhibitors and BRAF inhibitors
- (2018) Jason Chesney et al. MELANOMA RESEARCH
- Phase IIIb safety results from an expanded-access protocol of talimogene laherparepvec for patients with unresected, stage IIIB–IVM1c melanoma
- (2018) Jason Chesney et al. MELANOMA RESEARCH
- Molecular mechanism and cytotoxicity of allicin and all-trans retinoic acid against CD44 + versus CD117 + melanoma cells
- (2018) Bahareh Mohammadi Jobani et al. PHYTOMEDICINE
- Macrophages in skin melanoma-the key element in melanomagenesis (Review)
- (2018) Malgorzata Pieniazek et al. Oncology Letters
- Inhibition of cancer stem cell like cells by a synthetic retinoid
- (2018) Junwei Chen et al. Nature Communications
- Novel adherent CD11b+ Gr-1+ tumor-infiltrating cells initiate an immunosuppressive tumor microenvironment
- (2018) Takuya Tsubaki et al. Oncotarget
- The inhibition of malignant melanoma cell invasion of bone by the TLR7 agonist R848 is dependent upon pro-inflammatory cytokines produced by bone marrow macrophages
- (2018) Yoko Manome et al. Oncotarget
- Dying to Be Noticed: Epigenetic Regulation of Immunogenic Cell Death for Cancer Immunotherapy
- (2018) Brianne Cruickshank et al. Frontiers in Immunology
- Autoantibodies May Predict Immune-Related Toxicity: Results from a Phase I Study of Intralesional Bacillus Calmette–Guérin followed by Ipilimumab in Patients with Advanced Metastatic Melanoma
- (2018) Jessica Da Gama Duarte et al. Frontiers in Immunology
- Interferon-Gamma at the Crossroads of Tumor Immune Surveillance or Evasion
- (2018) Flávia Castro et al. Frontiers in Immunology
- Successful treatment with intralesional talimogene laherparepvec in two patients with immune checkpoint inhibitors refractory advanced melanoma
- (2018) Teofila Seremet et al. MELANOMA RESEARCH
- A potential novel option for cancer immunotherapy – TLR7 stimulation inhibits malignant melanoma bone invasion
- (2018) Takenobu Katagiri Oncotarget
- Fatal Toxic Effects Associated With Immune Checkpoint Inhibitors
- (2018) Daniel Y. Wang et al. JAMA Oncology
- Talimogene Laherparepvec (TVEC) for the Treatment of Advanced Melanoma: A Single-Institution Experience
- (2018) Matthew C. Perez et al. ANNALS OF SURGICAL ONCOLOGY
- Economic Evaluation of Talimogene Laherparepvec Plus Ipilimumab Combination Therapy vs Ipilimumab Monotherapy in Patients With Advanced Unresectable Melanoma
- (2018) Abdulaali R. Almutairi et al. JAMA Dermatology
- Topical treatment of all-trans retinoic acid inhibits murine melanoma partly by promoting CD8+ T-cell immunity
- (2017) Wei Yin et al. IMMUNOLOGY
- Immune system and melanoma biology: a balance between immunosurveillance and immune escape
- (2017) Anna Passarelli et al. Oncotarget
- Mycobacterium bovis Bacillus Calmette–Guérin Alters Melanoma Microenvironment Favoring Antitumor T Cell Responses and Improving M2 Macrophage Function
- (2017) Ricardo D. Lardone et al. Frontiers in Immunology
- Cost-Effectiveness of Nivolumab-Ipilimumab Combination Therapy Compared with Monotherapy for First-Line Treatment of Metastatic Melanoma in the United States
- (2017) Anna Oh et al. Journal of Managed Care & Specialty Pharmacy
- Insights into Local Tumor Microenvironment Immune Factors Associated with Regression of Cutaneous Melanoma Metastases by Mycobacterium bovis Bacille Calmette–Guérin
- (2017) Junbao Yang et al. Frontiers in Oncology
- Patterns of Clinical Response with Talimogene Laherparepvec (T-VEC) in Patients with Melanoma Treated in the OPTiM Phase III Clinical Trial
- (2016) Robert H. I. Andtbacka et al. ANNALS OF SURGICAL ONCOLOGY
- Combined treatment with ipilimumab and intratumoral interleukin-2 in pretreated patients with stage IV melanoma—safety and efficacy in a phase II study
- (2016) Benjamin Weide et al. CANCER IMMUNOLOGY IMMUNOTHERAPY
- Intratumoral interferon-gamma increases chemokine production but fails to increase T cell infiltration of human melanoma metastases
- (2016) Ileana S. Mauldin et al. CANCER IMMUNOLOGY IMMUNOTHERAPY
- Systematic review of the use of granulocyte–macrophage colony-stimulating factor in patients with advanced melanoma
- (2016) Christoph Hoeller et al. CANCER IMMUNOLOGY IMMUNOTHERAPY
- Human γδT-cell subsets and their involvement in tumor immunity
- (2016) Dang Wu et al. Cellular & Molecular Immunology
- RIG-I inhibits the MAPK-dependent proliferation of BRAF mutant melanoma cells via MKP-1
- (2016) Attila Szabo et al. CELLULAR SIGNALLING
- Differentiation-inducing and anti-proliferative activities of isoliquiritigenin and all-trans-retinoic acid on B16F0 melanoma cells: Mechanisms profiling by RNA-seq
- (2016) Xiaoyu Chen et al. GENE
- Cutaneous head and neck melanoma in OPTiM, a randomized phase 3 trial of talimogene laherparepvec versus granulocyte-macrophage colony-stimulating factor for the treatment of unresected stage IIIB/IIIC/IV melanoma
- (2016) Robert H. I. Andtbacka et al. HEAD AND NECK-JOURNAL FOR THE SCIENCES AND SPECIALTIES OF THE HEAD AND NECK
- Talimogene Laherparepvec in Combination With Ipilimumab in Previously Untreated, Unresectable Stage IIIB-IV Melanoma
- (2016) Igor Puzanov et al. JOURNAL OF CLINICAL ONCOLOGY
- Photosensitized rose Bengal-induced phototoxicity on human melanoma cell line under natural sunlight exposure
- (2016) Ajeet K. Srivastav et al. JOURNAL OF PHOTOCHEMISTRY AND PHOTOBIOLOGY B-BIOLOGY
- Intralesional PV-10 for in-transit melanoma-A single-center experience
- (2016) Jocelyn Lippey et al. JOURNAL OF SURGICAL ONCOLOGY
- An essential role for the IL-2 receptor in Treg cell function
- (2016) Takatoshi Chinen et al. NATURE IMMUNOLOGY
- Intralesional rose bengal in melanoma elicits tumor immunity via activation of dendritic cells by the release of high mobility group box 1
- (2016) Hao Liu et al. Oncotarget
- A phase I study of intratumoral ipilimumab and interleukin-2 in patients with advanced melanoma
- (2016) Abhijit Ray et al. Oncotarget
- Cancer statistics, 2015
- (2015) Rebecca L. Siegel et al. CA-A CANCER JOURNAL FOR CLINICIANS
- Malignant melanoma in organ transplant recipients: incidence, outcomes, and management strategies: a review of literature
- (2015) Martina Džambová et al. Dermatologic Therapy
- Health system costs of skin cancer and cost-effectiveness of skin cancer prevention and screening
- (2015) Louisa G. Gordon et al. EUROPEAN JOURNAL OF CANCER PREVENTION
- Talimogene Laherparepvec Improves Durable Response Rate in Patients With Advanced Melanoma
- (2015) Robert H.I. Andtbacka et al. JOURNAL OF CLINICAL ONCOLOGY
- Pooled Analysis of Long-Term Survival Data From Phase II and Phase III Trials of Ipilimumab in Unresectable or Metastatic Melanoma
- (2015) Dirk Schadendorf et al. JOURNAL OF CLINICAL ONCOLOGY
- Treatment of In-Transit Melanoma With Intralesional Bacillus Calmette-Guérin (BCG) and Topical Imiquimod 5% Cream
- (2015) Nour Kibbi et al. JOURNAL OF IMMUNOTHERAPY
- 100% Complete response rate in patients with cutaneous metastatic melanoma treated with intralesional interleukin (IL)-2, imiquimod, and topical retinoid combination therapy: Results of a case series
- (2015) Vivian Y. Shi et al. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY
- New Perspectives on the Role of Vitiligo in Immune Responses to Melanoma
- (2015) Katelyn T. Byrne et al. Oncotarget
- Pathologic Complete Response to Intralesional Interleukin-2 Therapy Associated with Improved Survival in Melanoma Patients with In-Transit Disease
- (2014) Saima Hassan et al. ANNALS OF SURGICAL ONCOLOGY
- Phase 2 Study of Intralesional PV-10 in Refractory Metastatic Melanoma
- (2014) John F. Thompson et al. ANNALS OF SURGICAL ONCOLOGY
- New insights into cancer immunoediting and its three component phases—elimination, equilibrium and escape
- (2014) Deepak Mittal et al. CURRENT OPINION IN IMMUNOLOGY
- Treatment of in-transit melanoma with intra-lesional interleukin-2: A systematic review
- (2014) Brett A. Byers et al. JOURNAL OF SURGICAL ONCOLOGY
- Intralesional Treatment of Stage III Metastatic Melanoma Patients with L19-IL2 Results in Sustained Clinical and Systemic Immunologic Responses
- (2014) B. Weide et al. Cancer Immunology Research
- Myeloid-Derived Suppressor Cells Predict Survival of Patients with Advanced Melanoma: Comparison with Regulatory T Cells and NY-ESO-1- or Melan-A-Specific T Cells
- (2013) B. Weide et al. CLINICAL CANCER RESEARCH
- T-Regulatory Cells: Key Players in Tumor Immune Escape and Angiogenesis
- (2012) A. Facciabene et al. CANCER RESEARCH
- Combined Intralesional Bacille Calmette-Guérin (BCG) and Topical Imiquimod for In-transit Melanoma
- (2012) Travis B. Kidner et al. JOURNAL OF IMMUNOTHERAPY
- Characterization of Human γδ T Lymphocytes Infiltrating Primary Malignant Melanomas
- (2012) Adriana Cordova et al. PLoS One
- Interleukin-2 Production by Dendritic Cells and its Immuno-Regulatory Functions
- (2012) Teresa Zelante et al. Frontiers in Immunology
- The Role of Retinoic Acid in Tolerance and Immunity
- (2011) Jason A. Hall et al. IMMUNITY
- Re-inventing intratumoral immunotherapy for melanoma
- (2011) Pierre L Triozzi et al. Immunotherapy
- Immunomodulation by Imiquimod in Patients with High-Risk Primary Melanoma
- (2011) Rupa Narayan et al. JOURNAL OF INVESTIGATIVE DERMATOLOGY
- Intra-lesional interleukin-2 for the treatment of in-transit melanoma
- (2011) Kirsty U. Boyd et al. JOURNAL OF SURGICAL ONCOLOGY
- Complete regression of subcutaneous and cutaneous metastatic melanoma with high-dose intralesional interleukin 2 in combination with topical imiquimod and retinoid cream
- (2011) Miki Shirakawa Garcia et al. MELANOMA RESEARCH
- High response rate after intratumoral treatment with interleukin-2
- (2010) Benjamin Weide et al. CANCER
- Local and Distant Immunity Induced by Intralesional Vaccination with an Oncolytic Herpes Virus Encoding GM-CSF in Patients with Stage IIIc and IV Melanoma
- (2009) Howard L. Kaufman et al. ANNALS OF SURGICAL ONCOLOGY
- Phase II Clinical Trial of a Granulocyte-Macrophage Colony-Stimulating Factor–Encoding, Second-Generation Oncolytic Herpesvirus in Patients With Unresectable Metastatic Melanoma
- (2009) Neil N. Senzer et al. JOURNAL OF CLINICAL ONCOLOGY
- Topical imiquimod and intralesional interleukin-2 increase activated lymphocytes and restore the Th1/Th2 balance in patients with metastatic melanoma
- (2008) D.S. Green et al. BRITISH JOURNAL OF DERMATOLOGY
- Chemoablation of metastatic melanoma using intralesional Rose Bengal
- (2008) John F. Thompson et al. MELANOMA RESEARCH
Find the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
SearchAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started